Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.67 |
| ▸ | CDK4 | P11802 | 3/20 | 0.61 |
| ▸ | CCND1 | P24385 | 3/20 | 0.61 |
| ▸ | CCND2 | P30279 | 3/20 | 0.61 |
| ▸ | CCND3 | P30281 | 3/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | USP2 | O75604 | 4/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CASP1 | P29466 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CASP7 | P55210 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803009 | 0.87 | GSK3B (0.72) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL4520036 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1CYP1A2USP2CLK4 | |
| SCHEMBL1600384 | 0.81 | MAPK8 (0.49) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL1600525 | 0.81 | CDK4 (0.65) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL1599121 | 0.78 | GSK3B (1.00) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL5803855 | 0.78 | GSK3B (1.00) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL4519423 | 0.77 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL5815034 | 0.77 | GSK3B (0.71) | GSK3BCDK4CCND1CCND2CCND3 | |
| SCHEMBL13966174 | 0.76 | ADORA2A (0.83) | ADORA2AADORA1 | |
| SCHEMBL5264386 | 0.76 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| EP-1670787-B1 | CYTOKINE INHIBITORS | ITHERX PHARMA INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2035005-A2 | THERAPY USING CYTOKINE INHIBITORS | Kemia, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | GSK3B 1135/4885CDK4 2071/4885CCND1 3713/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | GSK3B 1135/4885CDK4 2071/4885CCND1 3713/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | GSK3B 477/4885CDK4 1419/4885CCND1 2600/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | GSK3B 1135/4885CDK4 2071/4885CCND1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.